Project description DEENESFRITPL A pump and smart patch to treat diabetes As the prevalence of diabetes continues to increase across all ages in Europe, the life expectancy of patients suffering from Type 1 diabetes remains significantly reduced compared to healthy people. The EU-funded PRISMA project is developing an artificial pancreas as a treatment solution for patients with Type 1 diabetes. This device performs a continuous glucose measurement and pumps precise doses of insulin and other hormones needed for treatment. Specifically, a closed-loop artificial pancreas makes it possible to automatically control the blood glucose level using a mixture of multiple hormones simultaneously. The project will focus on a feasibility study to realise a small, lightweight smart patch able to deliver three hormones through silicon microneedles. Show the project objective Hide the project objective Objective More than 30 million people are living with diabetes in the EU, with a prevalence expected to grow to over 10% of the adult population by the year 2030. Despite modern treatments, the life expectancy of patients with type 1 diabetes remains reduced as compared to healthy people due to lack of efficient therapies. An “artificial pancreas” is the ultimate solution for such therapy: a device performing a continuous glucose measurement and pumping precise doses of insulin and other hormones needed for the treatment. The closed-loop artificial pancreases promises an agile solution where the diabetes patients may effectively feel relieved from their disease as the blood glucose level is automatically controlled using a mixture of multiple hormones simultaneously. Such an innovative technology alleviates the burden of carbohydrate counting and automatically ensuring the optimal glucose level at all times. However, a small, lightweight device which is able to administrate multiple hormones is still lacking. This proposal seeks to develop a novel micro-peristaltic pump on silicon, to be integrated with a transdermal smart patch loaded with the three hormones delivered by silicon microneedles. The PRISMA innovation is possible thanks to the achievements of the FET-OPEN project “BioWings”, where the concept of thin-film micropump using actuating materials has been prototyped. Fields of science medical and health sciencesclinical medicineendocrinologydiabetesnatural sciencesbiological sciencesbiochemistrybiomoleculescarbohydratesmedical and health sciencesmedical biotechnologytissue engineeringartificial pancreasnatural scienceschemical sciencesinorganic chemistrymetalloids Programme(s) H2020-EU.1.2. - EXCELLENT SCIENCE - Future and Emerging Technologies (FET) Main Programme H2020-EU.1.2.1. - FET Open Topic(s) FETOPEN-03-2018-2019-2020 - FET Innovation Launchpad Call for proposal H2020-FETOPEN-2018-2020 See other projects for this call Sub call H2020-FETOPEN-2018-2019-2020-4 Funding Scheme CSA-LSP - Coordination and support action Lump sum Coordinator DAY ONE SOCIETA A RESPONSABILITA LIMITATA Net EU contribution € 50 000,00 Address Viale dell oceano atlantico 18 00199 Roma rm Italy See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Centro (IT) Lazio Roma Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window EU contribution No data Participants (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all CEOX IVS Denmark Net EU contribution € 50 000,00 Address Paradisaeblevej 84 4 th 2500 Valby See on map Region Danmark Hovedstaden Byen København Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window EU contribution No data
